Marc Oczachowski, EDAP’s Chief Executive Officer, commented, We are very pleased by the growing adoption and global expansion of Ablatherm-HIFU, particularly in South America with our entrance into new markets in Argentina and Brazil. These recent approvals mark a clear milestone for our technology as Ablatherm-HIFU gains further traction as a proven non-invasive therapeutic solution for prostate cancer.